Press Releases

Skyscape Expands Senior Management Team

Marlborough, MA — Jun 07, 2018 — Skyscape® a leading provider of decision making tools to the healthcare community, announced the following recent executive appointment.

Ashok Mayya joins the management team as EVP - Sales, Marketing & Business Development. Prior to joining Skyscape, Mr. Mayya was the COO at Citron Pharma LLC, a leading provider of generic pharmaceuticals. He was responsible for and oversaw all the operations in the company. He played a key role in the sale of Citron Pharma to Rising Pharma for over $450M in 2016. Prior to this, Mr. Mayya was the COO and subsequently the CEO of Cedardale Distributors d/b/a Gen-Source Rx. Along with its CEO, he was responsible for growing the company to $100M in revenues. He successfully negotiated the sale of the company to Cardinal Health in 2014. His other experiences include being an Equity Analyst at an Investment Bank, Adams Harkness & Hill, and consultant to large Fund Management Organizations on Quantitative Portfolio Management. Mr. Mayya holds an MBA from The Wharton School and B. Tech from IIT-Bombay.

Commenting on the appointment, Skyscape’s CEO Mr. Sandeep Shah said, “We are pleased to welcome a highly talented individual such as Ashok; having been involved with successfully growing numerous prominent organizations. I personally look forward to working closely with the team as we execute our strategy to bring the best decision making tools to the benefit of the healthcare community.”

Skyscape Medpresso, Inc. has been a premier mobile technology pioneer, with a robust technology platform to support innovative and scalable brand marketing programs. Skyscape has expertise in delivering gold-standard content with world class publishers packaged as innovative tools.

KEEP IN TOUCH

     

Subscribe

Copyright © 2020. All rights reserved. Skyscape® is the registered trademark of Skyscape Medpresso, Inc.
All other trademarks, service marks and registrations are the intellectual properties of their respective owners.